IBT BIOSERVICES – Antibodies and proteins for infectious diseases
IBT Bioservices is the contract research division of Integrated BioTherapeutics, Inc. (IBT). IBT Bioservices offers a strong client-oriented research and development service focused on our area of expertise, infectious diseases. The team at IBT Bioservices has extensive experience in antiviral and antibacterial screening and model development. Tokyo Future Style offers reagents manufactured by IBT Bioservices.
Alphaviruses are arthropod-borne viruses that cause disease in humans and a wide range of domestic and agricultural animals. Interest in development of alphavirus therapeutics and vaccines has risen in recent years due to epidemics of Chikungunya virus (CHIKV) causing severe illness in Africa and Asia and concerns about possible use of Venezuelan equine encephalitis virus (VEE) as an agent of bioterrorism. IBT’s alphavirus reagent line covers Chikungunya and Venezuelan Equine Encephalitis Virus. Reagents include antisera and purified polyclonal antibodies. Specific targets include CHIKV, CHIKV E2 protein, and VEE.
Filoviruses such as Ebola, Sudan, Marburg and others are deadly pathogens which cause hemorrhagic fevers. The 2014 Ebola outbreak has caused more than 10,000 deaths. IBT offers the most comprehensive collection of commercially available reagents to support filovirus vaccine, therapeutic, and diagnostic research. IBT’s filovirus reagent line covers many filovirus species such as Ebola, Sudan, Marburg, Bundibugyo, and Reston and multiple virus components including key virus proteins and protein domains. Product types include recombinant proteins; monoclonal and polyclonal antibodies; antisera; etc. Specific targets covered include GP; L; NP; VP40; transmembrane and mucin-like domains; and others.
Influenza virus is a major pathogen which causes epidemics and pandemics worldwide. IBT’s influenza reagent line covers hemagglutinins for a range of influenza subtypes. The reagents are expressed as full length glycoprotein and demonstrate hemagglutination activity similar to the wild type virus. Specific targets include influenza hemagglutinins H1, H5, H7, H9, and H10.
IBT’s reagent line covers a range of viruses. Product types include antisera, and purified polyclonal antibodies against these viruses.
Specific targets covered include Crimean-Congo Hemorrhagic Fever Virus (CCHFV); Japanese Encephalitis Virus (JEV); Junin and Lassa Viruses; Rift Valley Fever Virus (RVFV); Vaccinia; etc.
Staphylococcus aureus is a bacterium which is a leading cause of hospital and community acquired infections. IBT’s S. aureus reagent line covers a range of virulence factors such as toxins, pore-forming toxins, superantigens, hemolysins, etc. Product types include recombinant, functionally active, purified proteins; monoclonal and polyclonal antibodies; etc. Specific targets covered include alpha hemolysin (alpha-toxin); gamma hemolysin (Hlg); Panton-Valentine Leukocidin (PVL); staphylococcal enterotoxin A (SEA); staphylococcal enterotoxin B (SEB); toxic shock syndrome toxin 1 (TSST-1); bicomponent toxins such as LukS-PV, LukF-PV, HlgB, and HlgC; and others.
Please contact us for any inquiries, questions, or information requests.
Tokyo Future Style, Inc.